The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma

CONCLUSIONS: Treatment with sorafenib plus TACE in TACE-refractory patients with intermediate-stage HCC resulted in longer intervals between TACE rounds, better maintenance of hepatic reserve, and significantly longer OS compared with repeated TACE.PMID:33906315 | DOI:10.31557/APJCP.2021.22.4.1217

Source: Asian Pacific Journal of Cancer Prevention - April 28, 2021 Category: Cancer & Oncology Authors: Masaki Kaibori Hideyuki Matsushima Morihiko Ishizaki Hisashi Kosaka Kousuke Matsui Shuji Kariya Kengo Yoshii Mitsugu Sekimoto Source Type: research